The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate

CSL

5 June 2020 - A vaccine is anticipated to be available in 2021 if clinical trials are successful.

CEPI, the Coalition for Epidemic Preparedness Innovations, CSL and The University of Queensland (UQ) today announced that they have entered into a new, significant partnering agreement to accelerate the development, manufacture and distribution of a COVID-19 vaccine candidate which has been pioneered by researchers at UQ. The agreement formalises the support provided by CSL to UQ and CEPI from the outset of the pandemic earlier this year.

CEPI and CSL will fund the development and manufacture of UQ’s “molecular clamp” enabled vaccine for COVID-19. Funding contributions will be used to provide support for the pending phase 1 safety study being led by UQ followed by subsequent late stage clinical trials, and industrial-scale manufacturing to allow the production of potentially millions of doses a year, should the product be approved.

Read CSL press release

Michael Wonder

Posted by:

Michael Wonder